Pembrolizumab monotherapy has been shown to be effective in a small cohort of heavily pretreated patients with ER+/HER2− metastatic breast cancer [42] and demonstrated meaningful antitumor activity in cancers with high TMB, including ER+/HER2− breast cancers [43]. Here, ESR1 is linked to cancer.